{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:15:11Z","timestamp":1761488111707},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/wco.0b013e32830f1e3b","type":"journal-article","created":{"date-parts":[[2008,9,3]],"date-time":"2008-09-03T11:04:35Z","timestamp":1220439875000},"page":"519-526","source":"Crossref","is-referenced-by-count":8,"title":["How to assess new drugs for neuropathies: advances in trial design and methodology"],"prefix":"10.1097","volume":"21","author":[{"given":"Pieter A","family":"van Doorn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingemar SJ","family":"Merkies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210206","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp.62.4.310","article-title":"Epidemiology of peripheral neuropathy","volume":"62","author":"Martyn","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R2-3-20210206","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3122\/jabfm.17.5.309","article-title":"The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients","volume":"17","author":"Mold","year":"2004","journal-title":"J Am Board Fam Pract"},{"key":"R3-3-20210206","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/diacare.27.7.1591","article-title":"Prevalence of lower-extremity disease in the US adult population \u2265 40 years of age with and without diabetes: 1999\u20132000 national health and nutrition examination survey","volume":"27","author":"Gregg","year":"2004","journal-title":"Diabetes Care"},{"key":"R4-3-20210206","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(04)16508-2","article-title":"Peripheral neuropathy","volume":"363","author":"England","year":"2004","journal-title":"Lancet"},{"key":"R5-3-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1085-9489.2006.00058.x","article-title":"Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.","volume":"11","year":"2006","journal-title":"J Peripher Nerv Syst"},{"key":"R6-3-20210206","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2337\/dc06-2479","article-title":"Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity","volume":"30","author":"Dyck","year":"2007","journal-title":"Diabetes Care"},{"key":"R7-3-20210206","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.nmd.2006.03.008","article-title":"136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A), 8-10 April 2005, Naarden, The Netherlands.","volume":"16","author":"Reilly","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"R8-3-20210206","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain\u2013Barr\u00e9 syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"issue":"Suppl 2","key":"R9-3-20210206","first-page":"S255","article-title":"Treatment of diabetic neuropathy and neuropathic pain: how far have we come?","volume":"31","author":"Ziegler","year":"2008","journal-title":"Diabetes Care"},{"issue":"Suppl","key":"R10-3-20210206","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain\u2013Barr\u00e9 syndrome","volume":"27","author":"Asbury","year":"1990","journal-title":"Ann Neurol"},{"key":"R11-3-20210206","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000052111","article-title":"Diagnostic and classification criteria for the Guillain\u2013Barr\u00e9 syndrome","volume":"45","author":"van der Mech\u00e9","year":"2001","journal-title":"Eur Neurol"},{"key":"R12-3-20210206","first-page":"617","article-title":"Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force.","volume":"41","year":"1991","journal-title":"Neurology"},{"key":"R16-3-20210206","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"R18-3-20210206","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1085-9489.2006.00059.x","article-title":"Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.","volume":"11","year":"2006","journal-title":"J Peripher Nerv Syst"},{"key":"R20-3-20210206","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1474-4422(07)70290-9","article-title":"Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations","volume":"6","author":"Hobart","year":"2007","journal-title":"Lancet Neurol"},{"key":"R22-3-20210206","first-page":"497","article-title":"A clinician's guide for conducting randomized trials in individual patients","volume":"139","author":"Guyatt","year":"1988","journal-title":"Can Med Assoc J"},{"key":"R23-3-20210206","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/bmj.312.7038.1069","article-title":"Randomised study of n of 1 trials versus standard practice","volume":"312","author":"Mahon","year":"1996","journal-title":"Br Med J"},{"key":"R24-3-20210206","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1085-9489.2005.10302.x","article-title":"Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.","volume":"10","year":"2005","journal-title":"J Peripher Nerv Syst"},{"key":"R25-3-20210206","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(97)12308-X","article-title":"Guillain\u2013Barr\u00e9 syndrome","volume":"352","author":"Hahn","year":"1998","journal-title":"Lancet"},{"key":"R26-3-20210206","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain\u2013Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"key":"R27-3-20210206","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/01.wco.0000169744.14288.d1","article-title":"Chronic inflammatory demyelinating polyneuropathy \u2013 update on pathogenesis, diagnostic criteria and therapy","volume":"18","author":"Koller","year":"2005","journal-title":"Curr Opin Neurol"},{"key":"R28-3-20210206","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.nmd.2005.12.003","article-title":"131st ENMC international workshop: selection of outcome measures for peripheral neuropathy clinical trials, 10-12 December 2004, Naarden, The Netherlands.","volume":"16","author":"Merkies","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"R29-3-20210206","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s00415-006-0515-2","article-title":"Determination of pain and response to methylprednisolone in Guillain\u2013Barr\u00e9 syndrome","volume":"254","author":"Ruts","year":"2007","journal-title":"J Neurol"},{"key":"R30-3-20210206","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial prednisolone in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet"},{"key":"R31-3-20210206","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","article-title":"Practice parameter: immunotherapy for Guillain\u2013Barr\u00e9 syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"61","author":"Hughes","year":"2003","journal-title":"Neurology"},{"key":"R32-3-20210206","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange\/Sandoglobulin Guillain-Barre Syndrome Trial Group.","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"R33-3-20210206","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome: randomised trial","volume":"363","author":"van Koningsveld","year":"2004","journal-title":"Lancet"},{"key":"R34-3-20210206","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/jnnp.2006.102731","article-title":"Treatment of Guillain\u2013Barr\u00e9 syndrome with mycophenolate mofetil: a pilot study","volume":"78","author":"Garssen","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R35-3-20210206","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","article-title":"Eculizumab prevents antiganglioside antibody-mediated neuropathy in a murine model","volume":"131","author":"Halstead","year":"2008","journal-title":"Brain"},{"key":"R36-3-20210206","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1212\/01.wnl.0000167549.09664.b8","article-title":"Distinguishing acute-onset CIDP from Guillain\u2013Barr\u00e9 syndrome with treatment related fluctuations","volume":"65","author":"Ruts","year":"2005","journal-title":"Neurology"},{"key":"R37-3-20210206","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"R39-3-20210206","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/brain\/awm144","article-title":"Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial","volume":"130","author":"Piepers","year":"2007","journal-title":"Brain"},{"key":"R40-3-20210206","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","article-title":"Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study","volume":"124","author":"Leger","year":"2001","journal-title":"Brain"},{"key":"R41-3-20210206","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/01.wnl.0000265055.28218.cc","article-title":"Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy","volume":"69","author":"Niermeijer","year":"2007","journal-title":"Neurology"},{"key":"R42-3-20210206","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(07)70172-2","article-title":"Skin biopsy in the management of peripheral neuropathy","volume":"6","author":"Sommer","year":"2007","journal-title":"Lancet Neurol"},{"key":"R44-3-20210206","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.phrs.2006.09.001","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot\u2013Marie\u2013Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]","volume":"54","author":"Pareyson","year":"2006","journal-title":"Pharmacol Res"},{"key":"R45-3-20210206","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0002-8703(00)90001-2","article-title":"Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics?","volume":"139","author":"Steyerberg","year":"2000","journal-title":"Am Heart J"},{"key":"R46-3-20210206","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jclinepi.2003.09.014","article-title":"Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements","volume":"57","author":"Hernandez","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"R47-3-20210206","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/neu.2005.22.511","article-title":"Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy","volume":"22","author":"Murray","year":"2005","journal-title":"J Neurotrauma"},{"key":"R48-3-20210206","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1191\/1740774505cn102oa","article-title":"A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain\u2013Barr\u00e9 syndrome","volume":"2","author":"Goodman","year":"2005","journal-title":"Clin Trials"},{"key":"R49-3-20210206","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(06)70603-2","article-title":"Clinical and electrophysiological predictors of respiratory failure in Guillain\u2013Barr\u00e9 syndrome: a prospective study","volume":"5","author":"Durand","year":"2006","journal-title":"Lancet Neurol"},{"key":"R50-3-20210206","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognostic scoring system for Guillain\u2013Barr\u00e9 syndrome","volume":"6","author":"van Koningsveld","year":"2007","journal-title":"Lancet Neurol"},{"key":"R51-3-20210206","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mus.10410","article-title":"Comparison between impairment and disability scales in immune-mediated polyneuropathies","volume":"28","author":"Merkies","year":"2003","journal-title":"Muscle Nerve"},{"key":"R52-3-20210206","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp.2005.076174","article-title":"Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients' own clinical judgement in immune-mediated polyneuropathies","volume":"77","author":"Merkies","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R55-3-20210206","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nmd.2007.08.004","article-title":"151st ENMC international workshop: Inflammatory Neuropathy Consortium, 13th-15th April 2007, Schiphol, The Netherlands.","volume":"18","author":"Lunn","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"R56-3-20210206","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1529-8027.2008.00169.x","article-title":"Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials","volume":"13","author":"van Nes","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"R57-3-20210206","doi-asserted-by":"crossref","DOI":"10.4324\/9781410600127","article-title":"Applying the Rasch model: fundamental measurement for the human sciences","author":"Bond","year":"2001"},{"key":"R58-3-20210206","doi-asserted-by":"crossref","first-page":"II28","DOI":"10.1097\/00005650-200009002-00007","article-title":"Item Response Theory and health outcomes measurement in the 21st century","volume":"38","author":"Hays","year":"2000","journal-title":"Med Care"},{"key":"R59-3-20210206","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"key":"R60-3-20210206","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0091-6749(98)70048-X","article-title":"Quality of life questionnaires: does statistically significant = clinically important?","volume":"102","author":"Juniper","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"R61-3-20210206","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/009286150303700105","article-title":"Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials","volume":"37","author":"Sloan","year":"2003","journal-title":"Drug Inform J"},{"key":"R62-3-20210206","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jclinepi.2005.07.011","article-title":"Distribution-based and anchor-based approaches provided different interpretability estimates for the Hydrocephalus Outcome Questionnaire","volume":"59","author":"Kulkarni","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"R63-3-20210206","article-title":"Statistical power analysis for the behavioural sciences","author":"Cohen","year":"1977"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WCO.0b013e32830f1e3b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T08:07:57Z","timestamp":1620979677000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019052-200810000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32830f1e3b","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}